- Home
- Publications
- Publication Search
- Publication Details
Title
DLL3: an emerging target in small cell lung cancer
Authors
Keywords
Antibody-drug conjugate (ADC), Bispecific T cell engager (BiTE®) antibody construct, Chimeric antigen receptor (CAR) T cell therapy, Delta-like ligand 3 (DLL3), Immuno-oncology therapy, Neuroendocrine, Small cell lung cancer (SCLC), Targeted therapy
Journal
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-06-18
DOI
10.1186/s13045-019-0745-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DLL 3 regulates the migration and invasion of small cell lung cancer by modulating Snail
- (2019) Megumi Furuta et al. CANCER SCIENCE
- LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
- (2019) T K Owonikoko et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
- (2018) Shirish M. Gadgeel et al. Journal of Thoracic Oncology
- Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer
- (2018) Kentaro Tanaka et al. LUNG CANCER
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
- (2018) Julie George et al. Nature Communications
- Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study.
- (2018) David Paul Carbone et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
- (2018) M Reck et al. ANNALS OF ONCOLOGY
- Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
- (2018) Marissa Spino et al. CLINICAL CANCER RESEARCH
- Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target
- (2018) Vadim S. Koshkin et al. CLINICAL CANCER RESEARCH
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
- (2018) Neal Ready et al. Journal of Thoracic Oncology
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
- (2017) Charles M Rudin et al. LANCET ONCOLOGY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- Unravelling the biology of SCLC: implications for therapy
- (2017) Joshua K. Sabari et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope
- (2017) Jonathan M. Lehman et al. Current Oncology Reports
- Small Cell Lung Cancer
- (2017) Gregory P. Kalemkerian et al. Journal of the National Comprehensive Cancer Network
- Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets
- (2017) Eumorphia G. Konstantakou et al. PLoS One
- Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions
- (2016) Matthias Klinger et al. IMMUNOLOGICAL REVIEWS
- New and emerging targeted treatments in advanced non-small-cell lung cancer
- (2016) Fred R Hirsch et al. LANCET
- Notch signalling in context
- (2016) Sarah J. Bray NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs
- (2016) Mark D. Borromeo et al. Cell Reports
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
- (2015) Laura R. Saunders et al. Science Translational Medicine
- Treatment decisions and survival for people with small-cell lung cancer
- (2014) H A Powell et al. BRITISH JOURNAL OF CANCER
- Small cell lung cancer: Where do we go from here?
- (2014) Lauren Averett Byers et al. CANCER
- Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
- (2014) Joachim von Pawel et al. JOURNAL OF CLINICAL ONCOLOGY
- ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers
- (2014) A. Augustyn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Different assemblies of Notch receptors coordinate the distribution of the major bronchial Clara, ciliated and neuroendocrine cells
- (2012) M. Morimoto et al. DEVELOPMENT
- Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis
- (2010) Gavin Chapman et al. HUMAN MOLECULAR GENETICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now